Arcturus Therapeutics initiated with bullish view at Canaccord, here’s why

Canaccord analyst Whitney Ijem last night initiated coverage of Arcturus Therapeutics with a Buy rating and $81 price target. In the genetic medicine space, many companies focus efforts on either the delivery vehicle or the cargo, but Arcturus has done both, the analyst tells investors in a research note. The firm says the company has developed proprietary and differentiated LNP delivery technology, as well as novel mRNA cargos allowing for options based on the application. It say Arcturus has a pipeline of medicines across a range of indications.